T
Thomas G. O'Riordan
Researcher at Stony Brook University
Publications - 71
Citations - 4723
Thomas G. O'Riordan is an academic researcher from Stony Brook University. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Mucociliary clearance. The author has an hindex of 32, co-authored 71 publications receiving 4098 citations. Previous affiliations of Thomas G. O'Riordan include Sanofi S.A. & Stony Brook University Hospital.
Papers
More filters
Journal ArticleDOI
Mucociliary clearance in the airways.
Journal ArticleDOI
Oral GS-5806 activity in a respiratory syncytial virus challenge study
John P. DeVincenzo,Richard J. Whitley,Richard L Mackman,Cecilia Scaglioni-Weinlich,Lisa Harrison,Eric Farrell,Stephen McBride,Rob Lambkin-Williams,Robert Jordan,Yan Xin,Srini Ramanathan,Thomas G. O'Riordan,Sandra A Lewis,Xiaoming Li,Seth Toback,Shao-Lee Lin,Jason W. Chien +16 more
TL;DR: Treatment with GS-5806 reduced the viral load and the severity of clinical disease in a challenge study of healthy adults, and adverse events, including low neutrophil counts and increased levels of alanine aminotransferase, were more common among participants receiving the drug.
Journal ArticleDOI
Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit.
Lucy B. Palmer,Gerald C. Smaldone,John J. Chen,Daniel Baram,Tao Duan,Melinda Monteforte,Marie Varela,Ann K. Tempone,Thomas G. O'Riordan,Feroza Daroowalla,Paul Richman +10 more
TL;DR: In critically ill patients with ventilator-associated tracheobronchitis, AA decrease VAP and other signs and symptoms of respiratory infection, facilitate weaning, and reduce bacterial resistance and use of systemic antibiotics.
Journal ArticleDOI
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.
Timothy S. Blackwell,Andrew M. Tager,Zea Borok,Bethany B. Moore,David A. Schwartz,Kevin J. Anstrom,Ziv Bar-Joseph,Peter B. Bitterman,Michael R. Blackburn,William Bradford,Kevin K. Brown,Harold A. Chapman,Harold R. Collard,Gregory P. Cosgrove,Robin R. Deterding,Ramona Doyle,Kevin R. Flaherty,Christine Kim Garcia,James S. Hagood,Craig A. Henke,Erica L. Herzog,Cory M. Hogaboam,Jeffrey C. Horowitz,Talmadge E. King,James E. Loyd,William Lawson,Clay B. Marsh,Paul W. Noble,Imre Noth,Dean Sheppard,Julie Olsson,Luis A. Ortiz,Thomas G. O'Riordan,Tim D. Oury,Ganesh Raghu,Jesse Roman,Patricia J. Sime,Thomas H. Sisson,Daniel J. Tschumperlin,Shelia M. Violette,Timothy E. Weaver,Rebecca G. Wells,Eric S. White,Naftali Kaminski,Fernando J. Martinez,Thomas A. Wynn,Victor J. Thannickal,Jerry P. Eu +47 more
TL;DR: Recommendations from a workshop aimed at coordinating research efforts and accelerating the development of IPF therapies provide a basis for directing future research and strategic planning by scientific, professional, and patient communities and the NHLBI.
Journal ArticleDOI
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial
Ganesh Raghu,Kevin K. Brown,Harold R. Collard,Vincent Cottin,Kevin F. Gibson,Robert J. Kaner,David J. Lederer,Fernando J. Martinez,Paul W. Noble,Jin Woo Song,Athol U. Wells,Timothy P.M. Whelan,Wim A. Wuyts,Emmanuel Moreau,Scott D. Patterson,Victoria Smith,Selina Bayly,Jason W. Chien,Qi Gong,Jenny Zhang,Thomas G. O'Riordan +20 more
TL;DR: The data do not support the use of simtuzumab for patients with IPF, and the most common adverse events were dyspnoea, cough, upper respiratory tract infection, and worsening of IPF.